Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
Marta Querol-VilasecaSònia SirisiLaura Molina-PorcelBeatriu MolinaJordi PeguerolesPaula Ferrer-RaventósRaúl Nuñez-LlavesOriol Dols-IcardoMircea BalasaMaria Florencia IulitaRafael BlesaOlivia BelbinJordi ClarimónJuan ForteaEllen GelpíRaquel Sánchez-ValleAlberto LleóPublished in: Neuropathology and applied neurobiology (2021)
We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.